GlassScriptPhysician profile
Michelle Dion
NPI 1982338588
$1,410.08
in general payments reported to CMS, 2019-2025
15 companies · $277 in 2025
The $277 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $173 · 2023: $857 · 2024: $103 · 2025: $277.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,237.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,237.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $324.74 | 2023-2024 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Janssen Pharmaceuticals, INC | $210.68 | 2022-2024 | Invega Sustenna, Invega Trinza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $178.30 | 2023 | |
| Alkermes, INC. | $157.91 | 2022-2023 | Aristada, Lybalvi |
| Tris Pharma INC | $107.03 | 2025 | Onyda Xr |
| Teva Pharmaceuticals USA, INC. | $99.86 | 2022-2023 | Uzedy, Austedo Xr, Austedo |
| Ucb, INC. | $70.89 | 2025 | Nayzilam, Fintepla |
| Indivior INC. | $69.28 | 2022-2023 | Perseris |
| Abbvie INC. | $55.08 | 2022-2024 | |
| Acadia Pharmaceuticals INC | $34.38 | 2025 | Daybue |
| Jazz Pharmaceuticals INC. | $27.87 | 2025 | |
| Neurelis, INC. | $23.29 | 2025 | Valtoco |
| Aquestive Therapeutics, INC. | $22.14 | 2024 | |
| Lundbeck LLC | $15.59 | 2023 | Rexulti |
| Aucta Pharmaceuticals, INC. | $13.04 | 2025 | Motpoly Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Dion listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.